Is it possible they have or are close to a partnership for liver and/or lung with an Asian partner?
My guess is they have a strong expression of interest from Asian partner on terms that allow Company to retain most/all of U.S. Bavi market, but the same Asian partner gets all of Europe and all of South America and the up front payment is good but not great.
So Company likes very much the retention of U.S. rights, but they want to involve some other serious BP bidders in the process (to increase the upfront payment) and that won't happen until after FDA approves Ph III trial design, ASCO sub-group data is on the table and front line MOS has been released-- all of which happens in May/June.
I don't think they are worried that the Asian BP offer will disappear any more than they are worried that liver cancer incidence in Asia is likely to decline.
News 
Market Data 
Discover 
